Shuchi Nahar's Weekend Blog!

Neuland Laboratories Limited -  Company Overview  Shuchi.P.Nahar -  @shuchi_nahar Neuland is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company operates in the market using two main business models - Generic Drug Substances (GDS) where they cater to the needs of the Generic players and Custom Manufacturing Solutions (CMS) where they primarily work with innovators by helping them bring critical products to the market. CDMO is the emerging growth segment of the company with 13 to 17 Molecules in development phase. 1.      Business Performance Neuland lab (NLL) has posted revenue of INR 2,054mn with 13.5% YoY increase, which was 4% below. The revenue growth was mainly driven by the CMS segment, led by 32 molecules (Development + Commercialize) with speciality API segment, which grew by 33.2% in Q1FY21. EBITDA margin expanded by 622bps to...

India Emerging as a Next Biologic Drug Hub SHUCHI.P.NAHAR The Indian pharmaceutical companies always had strong chemistry skills to work on small molecules to make generic drugs, but they lacked skills, people and ecosystem to work on large molecules to come up with reverse engineered versions of biotech drugs, many experts complain. However, it is beginning to change.   'India: the emerging hub for biologics and biosimilars', the Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline. Further, India has 95 approved biosimilars in the domestic market, more than any other country in the world. Biologics are the biological products regulated under the rules of the Food and Drug Administration (FDA). They are used to either diagnose, prevent, treat, or cure various medical conditions.  Significantly, biologics are large, complex, and diverse molecules produced through biotec...